Analysts Set Expectations for STOK Q3 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Stoke Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.55) per share for the quarter. HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.22 EPS.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday. Finally, Chardan Capital restated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Stock Up 0.8 %

Shares of NASDAQ STOK opened at $8.33 on Friday. The company has a market capitalization of $441.22 million, a PE ratio of -3.97 and a beta of 0.99. Stoke Therapeutics has a twelve month low of $5.80 and a twelve month high of $17.58. The firm has a fifty day simple moving average of $9.49 and a 200 day simple moving average of $11.49.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 over the last ninety days. 11.30% of the stock is owned by company insiders.

Institutional Trading of Stoke Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP grew its holdings in Stoke Therapeutics by 10.1% during the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after buying an additional 471,240 shares in the last quarter. Baker BROS. Advisors LP grew its stake in shares of Stoke Therapeutics by 6.1% in the 4th quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock worth $51,111,000 after acquiring an additional 265,395 shares in the last quarter. Toronto Dominion Bank purchased a new stake in shares of Stoke Therapeutics in the fourth quarter valued at about $35,001,000. State Street Corp lifted its position in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after purchasing an additional 137,145 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in Stoke Therapeutics by 2.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock worth $14,901,000 after purchasing an additional 38,446 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.